vs
Side-by-side financial comparison of Azenta, Inc. (AZTA) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.
Azenta, Inc. is the larger business by last-quarter revenue ($148.6M vs $83.1M, roughly 1.8× PROCEPT BioRobotics Corp). Azenta, Inc. runs the higher net margin — -10.4% vs -38.1%, a 27.7% gap on every dollar of revenue. On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs 0.8%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs 4.4%).
Azenta, was founded in 1978, and is based in Chelmsford, Massachusetts, United States. The company is a provider of life sciences services including genomics, cryogenic storage, automation, and informatics.
PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.
AZTA vs PRCT — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $148.6M | $83.1M |
| Net Profit | $-15.4M | $-31.6M |
| Gross Margin | 42.9% | 64.9% |
| Operating Margin | -4.9% | -4.1% |
| Net Margin | -10.4% | -38.1% |
| Revenue YoY | 0.8% | 20.2% |
| Net Profit YoY | -15.7% | -27.9% |
| EPS (diluted) | $-0.34 | $-0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $83.1M | ||
| Q4 25 | $148.6M | $76.4M | ||
| Q3 25 | $159.2M | $83.3M | ||
| Q2 25 | $143.9M | $79.2M | ||
| Q1 25 | $143.3M | $69.2M | ||
| Q4 24 | $147.4M | $68.2M | ||
| Q3 24 | $150.6M | $58.4M | ||
| Q2 24 | $144.3M | $53.4M |
| Q1 26 | — | $-31.6M | ||
| Q4 25 | $-15.4M | $-29.8M | ||
| Q3 25 | $50.9M | $-21.4M | ||
| Q2 25 | $-48.0M | $-19.6M | ||
| Q1 25 | $-47.7M | $-24.7M | ||
| Q4 24 | $-11.0M | $-18.9M | ||
| Q3 24 | $-6.6M | $-21.0M | ||
| Q2 24 | $-6.6M | $-25.6M |
| Q1 26 | — | 64.9% | ||
| Q4 25 | 42.9% | 60.6% | ||
| Q3 25 | 45.4% | 64.8% | ||
| Q2 25 | 46.2% | 65.4% | ||
| Q1 25 | 43.8% | 63.9% | ||
| Q4 24 | 46.7% | 64.0% | ||
| Q3 24 | 45.5% | 63.2% | ||
| Q2 24 | 44.8% | 59.0% |
| Q1 26 | — | -4.1% | ||
| Q4 25 | -4.9% | -40.6% | ||
| Q3 25 | 1.2% | -27.8% | ||
| Q2 25 | -1.3% | -28.0% | ||
| Q1 25 | -12.7% | -39.7% | ||
| Q4 24 | -5.9% | -28.9% | ||
| Q3 24 | -3.1% | -38.4% | ||
| Q2 24 | -4.9% | -50.3% |
| Q1 26 | — | -38.1% | ||
| Q4 25 | -10.4% | -39.1% | ||
| Q3 25 | 32.0% | -25.7% | ||
| Q2 25 | -33.4% | -24.7% | ||
| Q1 25 | -33.3% | -35.8% | ||
| Q4 24 | -7.5% | -27.6% | ||
| Q3 24 | -4.4% | -35.9% | ||
| Q2 24 | -4.5% | -48.0% |
| Q1 26 | — | $-0.56 | ||
| Q4 25 | $-0.34 | $-0.54 | ||
| Q3 25 | $1.12 | $-0.38 | ||
| Q2 25 | $-1.05 | $-0.35 | ||
| Q1 25 | $-1.04 | $-0.45 | ||
| Q4 24 | $-0.25 | $-0.34 | ||
| Q3 24 | $-0.25 | $-0.40 | ||
| Q2 24 | $-0.12 | $-0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $336.6M | $245.6M |
| Total DebtLower is stronger | — | $51.7M |
| Stockholders' EquityBook value | $1.7B | $347.7M |
| Total Assets | $2.1B | $487.1M |
| Debt / EquityLower = less leverage | — | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $245.6M | ||
| Q4 25 | $336.6M | $286.5M | ||
| Q3 25 | $279.8M | $294.3M | ||
| Q2 25 | $270.0M | $302.7M | ||
| Q1 25 | $253.6M | $316.2M | ||
| Q4 24 | $377.5M | $333.7M | ||
| Q3 24 | $280.0M | $196.8M | ||
| Q2 24 | $336.5M | $214.1M |
| Q1 26 | — | $51.7M | ||
| Q4 25 | — | $51.6M | ||
| Q3 25 | — | $51.6M | ||
| Q2 25 | — | $51.5M | ||
| Q1 25 | — | $51.5M | ||
| Q4 24 | — | $51.5M | ||
| Q3 24 | — | $51.4M | ||
| Q2 24 | — | $51.4M |
| Q1 26 | — | $347.7M | ||
| Q4 25 | $1.7B | $365.9M | ||
| Q3 25 | $1.7B | $380.3M | ||
| Q2 25 | $1.7B | $385.8M | ||
| Q1 25 | $1.7B | $389.2M | ||
| Q4 24 | $1.7B | $402.2M | ||
| Q3 24 | $1.8B | $241.2M | ||
| Q2 24 | $2.0B | $251.8M |
| Q1 26 | — | $487.1M | ||
| Q4 25 | $2.1B | $508.1M | ||
| Q3 25 | $2.1B | $511.5M | ||
| Q2 25 | $2.0B | $513.1M | ||
| Q1 25 | $2.0B | $519.4M | ||
| Q4 24 | $2.0B | $534.0M | ||
| Q3 24 | $2.1B | $374.1M | ||
| Q2 24 | $2.3B | $374.4M |
| Q1 26 | — | 0.15× | ||
| Q4 25 | — | 0.14× | ||
| Q3 25 | — | 0.14× | ||
| Q2 25 | — | 0.13× | ||
| Q1 25 | — | 0.13× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.20× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.8M | — |
| Free Cash FlowOCF − Capex | $14.7M | — |
| FCF MarginFCF / Revenue | 9.9% | — |
| Capex IntensityCapex / Revenue | 4.2% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $30.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $20.8M | $-10.3M | ||
| Q3 25 | $2.2M | $-6.6M | ||
| Q2 25 | $25.8M | $-15.0M | ||
| Q1 25 | $14.4M | $-17.0M | ||
| Q4 24 | $29.8M | $-32.4M | ||
| Q3 24 | $17.7M | $-18.8M | ||
| Q2 24 | $9.8M | $-15.7M |
| Q1 26 | — | — | ||
| Q4 25 | $14.7M | $-12.2M | ||
| Q3 25 | $-5.7M | $-9.5M | ||
| Q2 25 | $15.0M | $-17.8M | ||
| Q1 25 | $7.0M | $-18.8M | ||
| Q4 24 | $22.0M | $-33.6M | ||
| Q3 24 | $8.3M | $-19.0M | ||
| Q2 24 | $1.3M | $-16.8M |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | -15.9% | ||
| Q3 25 | -3.6% | -11.4% | ||
| Q2 25 | 10.4% | -22.5% | ||
| Q1 25 | 4.9% | -27.2% | ||
| Q4 24 | 15.0% | -49.2% | ||
| Q3 24 | 5.5% | -32.6% | ||
| Q2 24 | 0.9% | -31.4% |
| Q1 26 | — | — | ||
| Q4 25 | 4.2% | 2.4% | ||
| Q3 25 | 4.9% | 3.4% | ||
| Q2 25 | 7.5% | 3.5% | ||
| Q1 25 | 5.2% | 2.7% | ||
| Q4 24 | 5.3% | 1.7% | ||
| Q3 24 | 6.2% | 0.4% | ||
| Q2 24 | 5.9% | 2.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.04× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AZTA
| Multiomics | $67.2M | 45% |
| Core Products | $47.6M | 32% |
| Sample Repository Solutions | $33.8M | 23% |
PRCT
| Handpieces and other consumables | $43.0M | 52% |
| System sales and rentals | $23.4M | 28% |
| Other | $11.1M | 13% |
| Service | $5.6M | 7% |
